TRIM21 and systemic lupus erythematosus: TRIM21 was first described as a target for autoantibody production in SLE and Sjögren's syndrome (SS) [20]–[22] and was amongst the first of the TRIM proteins shown to negatively regulate IFN production [7], [23].